




PHARMACEUTICAL 2023

Acurx Pharmaceuticals Inc.
Rank 290 of 446





PHARMACEUTICAL 2023

Acurx Pharmaceuticals Inc.
Rank 290 of 446

The relative strengths and weaknesses of Acurx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acurx Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 871% points. The greatest weakness of Acurx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 136% points.

The company's Economic Capital Ratio, given in the ranking table, is 8.6%, being 35% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,062
Liabilities, Non-Current	0
Other Assets	9,377
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property and Equipment	0
Research and Development	4,754
Selling, General and Administrative Expense	7,339

Output Variable	Value in 1000 USD
Assets	9,377
Liabilities	2,062
Expenses	12,093
Revenues	0
Stockholders Equity	7,315
Net Income	-12,093
Comprehensive Net Income	-12,093
Economic Capital Ratio	8.6%